La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Heilongjiang ZBD Pharmaceutical Bilan de santé
Santé financière contrôle des critères 5/6
Heilongjiang ZBD Pharmaceutical has a total shareholder equity of CN¥8.3B and total debt of CN¥3.3B, which brings its debt-to-equity ratio to 39.5%. Its total assets and total liabilities are CN¥12.9B and CN¥4.5B respectively. Heilongjiang ZBD Pharmaceutical's EBIT is CN¥259.5M making its interest coverage ratio -0.8. It has cash and short-term investments of CN¥1.4B.
Informations clés
39.5%
Ratio d'endettement
CN¥3.29b
Dette
| Ratio de couverture des intérêts | -0.8x |
| Argent liquide | CN¥1.40b |
| Fonds propres | CN¥8.33b |
| Total du passif | CN¥4.55b |
| Total des actifs | CN¥12.88b |
Mises à jour récentes de la santé financière
Analyse de la situation financière
Passif à court terme: 603567's short term assets (CN¥7.6B) exceed its short term liabilities (CN¥3.0B).
Passif à long terme: 603567's short term assets (CN¥7.6B) exceed its long term liabilities (CN¥1.6B).
Historique et analyse du ratio d'endettement
Niveau d'endettement: 603567's net debt to equity ratio (22.7%) is considered satisfactory.
Réduire la dette: 603567's debt to equity ratio has reduced from 41.7% to 39.5% over the past 5 years.
Couverture de la dette: 603567's operating cash flow is negative, therefore debt is not well covered.
Couverture des intérêts: 603567 earns more interest than it pays, so coverage of interest payments is not a concern.